In Situ Maleimide Bridging of Disulfides and a New Approach to Protein PEGylation by Schumacher, Felix F. et al.
Published: January 27, 2011
r2011 American Chemical Society 132 dx.doi.org/10.1021/bc1004685|Bioconjugate Chem. 2011, 22, 132–136
COMMUNICATION
pubs.acs.org/bc
In Situ Maleimide Bridging of Disulfides and a New Approach
to Protein PEGylation
Felix F. Schumacher, Muriel Nobles,
† Chris P. Ryan, Mark E. B. Smith, Andrew Tinker,
† Stephen Caddick,*
and James R. Baker*
Department of Chemistry, University College London, 20 Gordon Street, London,WC1H OAJ, United Kingdom
†Department of Medicine, University College London, 5 University Street, London, WC1E 6JJ, United Kingdom
b S Supporting Information
ABSTRACT: The introduction of non-natural entities into
proteinsbychemicalmodiﬁcationhasnumerousapplications
in fundamental biological science and for the development
and manipulation of peptide and protein therapeutics. The
reduction of native disulﬁde bonds provides a convenient
method to access two nucleophilic cysteine residues that can
serve as ideal attachment points for such chemical modiﬁca-
tion. The optimum bioconjugation strategy utilizing these
cysteine residues should include the reconstruction of a bridge to mimic the role of the disulﬁde bond, maintaining structure and
stability of the protein. Furthermore, the bridging chemical modiﬁcation should be as rapid as possible to prevent problems
associated withprotein unfolding, aggregation, or disulﬁde scrambling. This study reports on an in situ disulﬁdereduction-bridging
strategythatensuresrapidsequestrationofthefreecysteineresiduesinabridge,usingdithiomaleimides.Thisapproachisthenused
to PEGylate the peptide hormone somatostatin and retention of biological activity is demonstrated.
A
commonapproachtomanipulatingthepropertiesofprotein
therapeutics involves their derivatization via amino acid
selective bioconjugation protocols.
1,2 Functional moieties regu-
larly attached to proteins in this manner include ﬂuorophores or
radiolabels for imaging applications
2 and polymers such as
poly(ethylene glycol) (PEG) to increase in vivo stability, solu-
bility, and reduce immunogenicity.
3 The majority of bioconjuga-
tion methods currently employed use the nucleophilic residues
lysineorcysteineforfunctionalizationwithelectrophilicreagents.A
drawback with lysine modiﬁcation is that numerous lysine resi-
dues are commonly accessible on the protein surface, and thus,
such reactions often aﬀord mixtures of products.
3 In contrast,
cysteine has a relatively low natural abundance
4 and when pre-
sent is often tied up in a disulﬁde bridge. The introduction of a
cysteine by mutagenesis is routinely used to provide a single
point of attachment; however, in some situations the mutagen-
esis may not be practical or the resultant mutant may have unde-
sirable properties such as susceptibility to dimerization or disulﬁde
scrambling.
5 An alternative strategy is to release active cysteine
residuesbyreduction ofnativedisulﬁdebonds.
6Itisnotablethat
manypotentialproteintherapeuticscontainaccessibledisulﬁdes,
which serve to aﬀord increased stability to the protein struc-
tures.
7 Herein lies the challenge, as by cleaving such disulﬁde
bonds, this stabilizing eﬀect is lost. A solution is to deploy
reagents that serve to rebridge the two cysteine residues, mim-
ickingthe role ofthe disulﬁde bond, and thus retaining thestruc-
ture and function of the proteins. To this end, we have recently
reportedontheapplicationofbromomaleimidesforthebridging
of a reduced disulﬁde, incorporating a rigid two-carbon spacer
between the two cysteine thiols of the peptide hormone somato-
statin (Figure 1a, reagent 1).
8-10
Thisbridgingprotocolandtherelatedproceduredescribedby
Brocchini and co-workers
7,11-13 both still suﬀer a potential
limitation. They require the disulﬁde bond to be initially cleaved
withreducingagentstoaﬀordthetwofreecysteinestowhichthe
bridgingreagentisthenadded.Thereisariskthatinthetimethat
has elapsed between disulﬁde cleavage and completion of the
bridging event structurally sensitive proteins may have started to
unfold. Even if the opening of a disulﬁde bond has no immediate
negative eﬀects on the protein structure, free thiols can lead to
aggregation
14 and disulﬁde scrambling.
15 To prevent this pro-
blem, the optimum bridging strategy must limit the time the
cysteines are free before they are captured by the reagent. Our
strategy to achieve this involves developing new bridging re-
agentsthatcanbeusedintandemwithareducingagent,suchthat
as the free cysteines are revealed they are immediately sequestered
in a bridge. Herein, we report on a selection of new maleimide-
basedreagentsfordisulﬁdebridgingandrevealtheﬁrstexamplesof
an in situ procedure using these reagents. We also describe new
reagents for the PEGylation of disulﬁdes and demonstrate reten-
tion of biological activity of bridged somatostatin analogues.
Somatostatin is a cyclic peptide that plays a key role in regu-
lating the endocrine system by inhibiting the release of various
hormones, including growth hormone, insulin, and secretin.
Received: October 25, 2010
Revised: January 12, 2011133 dx.doi.org/10.1021/bc1004685 |Bioconjugate Chem. 2011, 22, 132–136
Bioconjugate Chemistry COMMUNICATION
Somatostatincannotbeusedclinically,becauseithasashorthalf-
lifeinvivo;
16however,stableanalogueshavebeendevelopedand
are widely employed in the treatment of acromegaly and gastro-
enteropancreatic tumors.
17,18 Somatostatin contains a single
disulﬁde bridge between Cys3 and Cys14, which serves to main-
tainthebeta-turnthathasbeenidentiﬁedasthebindingmotiffor
the interaction with a family of G-protein coupled receptors
(somatostatin receptors 1-5).
19
Having shown previously that dibromomaleimide 1 would
eﬃcientlybridgethedisulﬁdeofsomatostatin,
9weperceivedthat
dichloromaleimide 2
20 and diodomaleimide 3
21 would exhibit
similar but distinct reactivity in this reaction. Treatment of
somatostatin with TCEP followed by dichloro- and diodomale-
imide did indeed lead to eﬀective bridging (Figure 1), and com-
parison with dibromomaleimide led to the following order of
reactivity: diiodomaleimide > dibromomaleimide > dichloroma-
leimide (Figure 1b). This order of reactivity, which was further
conﬁrmed by stopped-ﬂow measurements (see supplementary
Table 1 in the Supporting Information), suggests that the rate-
determining step for this conjugate addition-elimination se-
quenceinvolveslossoftheleavinggroup.Thus,theiodidesasthe
best leaving groups lead to the fastest reaction.
The susceptibilityofdithiomaleimidestobecleavedbythiols
9
illustrated that thiol-exchange reactions were facile in these sys-
tems. This highlighted to us the potential of dithiomaleimides as
newdisulﬁdebridgingreagentsthemselves.Thus,wesynthesized
dimercaptoethanolmaleimide 4 and dithiophenolmaleimide 5
22
to evaluate their reactivity. Treatment of somatostatin with TCEP
followedby1equivofdimercaptoethanolmaleimide4ledto68%
yield of bridged compound 6 after 1 h (Figure 1c). Prolonged
reaction times did not improve the isolated yield of product,
which suggested that an equilibrium mixture had been formed as
a consequence of competition between the aliphatic thiols in the
peptide and mercaptoethanol. By simply increasing the amount
ofdimercaptoethanolmaleimide4to10equiv,weobservedcom-
plete conversion to bridged somatostatin after 1 h. In contrast,
the use of thiophenol as an improved leaving group led to com-
plete bridging after 10 min with just 1 equiv of reagent 5
(Figure1d),ataratecomparabletothatofdibromomaleimide1.
These results demonstrate the potential for various haloma-
leimides and thiomaleimides to serve as cysteine reactive re-
agents and to form maleimide bridged disulﬁdes. Our next goal
was to test whether any of these reagents would be suitable for
the in situ disulﬁde cleavage-bridging sequence. Crucially, the
reagents would have to be tolerant of the presence of the redu-
cing agent TCEP. In a series of test reactions, we found that the
halomaleimides showed a greater reactivity toward TCEP than
the dithiomaleimides (see supplementary Table 2 intheSuppor-
ting Information), suggesting that the dithiomaleimides would
be more likely to be suitable for an in situ protocol. For com-
parison, we chose to trial both the dibromomaleimide 1 and
dithiophenolmaleimide 5 in in situ studies (Figure 2a). The
maleimides (5 equiv) were thus added to somatostatin, followed
by varying quantities of TCEP. In the case of dibromomaleimide
1, somatostatin bridging was observed to aﬀord up to 60%
bridged somatostatin (Figure 2b). Notably, some unreacted
somatostatin remained, suggesting that the TCEP-dibromo-
maleimide side reaction was impeding the desired sequence.
Furthermore, the formation of side products was observed, which
appear, by MS analysis, to be somatostatin-maleimide-TCEP con-
jugates. In contrast, treatment of somatostatin with dithiophe-
nolmaleimide 5 led to near-quantitative bridging on the addition
Figure 1. Dihalomaleimides and dithiomaleimides bridge reduced somatostatin. (a) The bridging of somatostatin with reagents 1-5. (b) LCMS data
on the bridging of reduced somatostatin with the dihalomaleimides 1-3. (c) LCMS data on the bridging of reduced somatostatin with
dimercaptoethanolmaleimide 4. (d) LCMS data on the bridging of reduced somatostatin with dithiophenolmaleimide 5.134 dx.doi.org/10.1021/bc1004685 |Bioconjugate Chem. 2011, 22, 132–136
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of 3-5 equiv of TCEP (Figure 2c). This bridging reaction is
complete within 20 min (Figure 2d), illustrating the eﬃciency of
the reaction sequence. Clearly, by tempering the reactivity of the
maleimidetoTCEPcrossreactivity,selectivityforthedesireddisul-
ﬁde reduction-bridging sequence had been obtained. Dithiophe-
nolmaleimide 5 therefore represents, to our knowledge, the ﬁrst
reagent reported for the eﬃcient in situ bridging of disulﬁdes.
Wealsoreasonedthat,inplaceofTCEP,thiolreducingagents
could be employed in this in situ bridging. However, at pH 6.2,
the pH at which reduced somatostatin is maintained in solu-
tion,
12 we observed negligible disulﬁde cleavage with mercap-
toethanol or DTT. Selenols, however, are known to catalyze
disulﬁde cleavage,
23 and we found that benzeneselenol could be
used eﬀectively with dithiophenolmaleimide to carry out the in
situ bridging (Figure 3). In this reaction, it is the thiophenol
released from the maleimide that serves as the reducing agent in
conjunction with the selenol. Control reactions showed that the
selenol was unable to reduce the disulﬁde in the absence of the
thiophenolmaleimide (see Supporting Information).
Stabilized analogues of somatostatin are clinically important
due to the short invivo half-life of the peptide itself, and thus, we
aimed to synthesize a new PEGylated somatostatin employing
thismethodology(Figure4a).WesynthesizedanN-PEGdibromo-
maleimide 7 and an N-PEG dithiophenolmaleimide 8, via single-
step procedures utilizing a Mitsunobu reaction. The dibromoma-
leimide-PEG was inserted into somatostatin by the sequential
protocol of disulﬁde reduction followed by addition of the bridging
reagent (conditions a), while the dithiophenolmaleimide-PEG
was inserted by the in situ disulﬁde reduction-bridging protocol
(conditions b). In both reactions, the PEGylated somatostatin was
formed near-quantitatively in under 20 min.
To test whether the bridging modiﬁcation had a deleterious
eﬀect on the activity of the resultant somatostatin analogues, we
tested the simple maleimide-bridged analogue 6, the PEGylated
Figure 2. In situ bridging of somatostatin. (a)The in situ protocol. (b) LCMS data showing the eﬀect ofvarying TCEPequiv on the in situ bridging of
somatostatin using dibromomaleimide 1 (5 equiv) after 1 h. (c) LCMS data showing the eﬀect of varying TCEP equiv on the in situ bridging of
somatostatin using dithiophenolmaleimide 5 (5 equiv) after 1 h. (d) LCMS data over 2 h showing the in situ bridging of somatostatin using the
optimized conditions of dithiophenolmaleimide 5 (5 equiv) and TCEP (3 equiv).
Figure 3. Selenol-mediated in situ bridging of somatostatin. The
reaction was monitored by LCMS over 2 h.135 dx.doi.org/10.1021/bc1004685 |Bioconjugate Chem. 2011, 22, 132–136
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analogue 9, and the ﬂuorescein-labeled analogue reported by us
previously
9 in a signaling assay. G-protein gated inwardly rectify-
ing potassium (GIRK) channels are activated by seven helix
receptors coupling to the inhibitory family of G-protein and
speciﬁcally by the direct binding of the Gβγ subunit to the
channel subunits.
24 In the pituitary, the activation of GIRK
channels via somatostatin receptors (SSTR) contributes to the
inhibition of hormone release.
25 To model this system, we
Figure4. SynthesisofthePEGylatedsomatostatinandbiologicalactivityofsomatostatinanalogues.(a)SynthesisofN-PEG-dibromomaleimide7and
N-PEG-dithiophenolmaleimide 8, and their insertion into somatostatin via the stepwise protocol (conditions a) or the in situ protocol (conditions b),
respectively. Thereactionswere monitoredby LCMSover 1h.(b)Representative current traces recorded fromGIRK1/2A cellline expressing SSTR2.
Cells were clamped at -60 mV, and 20 μM of somatostatin or its derivatives was applied for 20 s. Dotted lines indicate zero current. (c) Amplitude of
currentsactivatedbysomatostatinandanalogues.Peakvaluesofcurrentsinsampleconditions,afterpretreatmentofcellswithPertussistoxinfor24h,or
preincubation with the GIRK inhibitor TertiapinQ, 100 nM for 5 min. A t test was used to evaluate the observed eﬀects. ** p < 0.01, *** p < 0.001.136 dx.doi.org/10.1021/bc1004685 |Bioconjugate Chem. 2011, 22, 132–136
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transiently transfected human SSTR2 into HEK293 cells stably
expressing Kir3.1 and Kir3.2 and examinedfor current activation
after agonist application using whole-cell patch clamping. All
three analogues were able to activate currents in a manner com-
parable to that of unmodiﬁed somatostatin (Figure 4b). The
response was inhibited by incubation with pertussis toxin de-
monstrating receptor-mediated activation of inhibitory G-pro-
teins and by tertiapin a relatively speciﬁc inhibitor of GIRK
channels (Figure 4c).
’CONCLUSION
We have found that a selection of dihalo- and dithiomalei-
mides provide reagents of tunable reactivity for the chemical
modiﬁcation and bridging of disulﬁde bonds. Via an improved
bridging protocol, we have shown that dithiophenolmaleimides
can be eﬀectively employed in situ with a reducing agent to
ensure rapid sequestration of the free cysteine residues. This will
serve to limit the problems associated with reducing disulﬁde
bonds toaﬀord free cysteines for bioconjugation, such as protein
unfolding, aggregation, and disulﬁde scrambling. We have also
described new reagents for the PEGylation of proteins, a process
known to increase in vivo stability and solubility and reduce
immunogenicityof protein therapeutics,
3anddemonstratedthat
PEGylatedandﬂuorescentsomatostatinanaloguesretainagonist
activity. We suggest that the use of bridging reagents via in situ
protocols will preclude many of the previous limitations of
disulﬁde modiﬁcation, broadening the scope of proteins that
can be manipulated in this manner.
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